Registry-listed formulations

Balcinrenone · chembl:CHEMBL3916929

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

4 source entries across 1 studies. This list may not include all unresolved or historical entries.

  • balcinrenoneRegistry product

    Molecular identity unconfirmed

    Formulation reported by source: CAPSULE

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source
  • balcinrenoneRegistry product

    Molecular identity unconfirmed

    Formulation reported by source: CAPSULE

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source
  • Balcinrenone 50mg CapsuleRegistry intervention

    Linked study entry; product equivalence not established

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source
  • Balcinrenone 100mg CapsuleRegistry intervention

    Linked study entry; product equivalence not established

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Phase 2
1
50%
Phase 1
1
50%

Phase Distribution

1

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 2Efficacy & side effects
1(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Completed(2)

Detailed Status

Completed2

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (50.0%)
Phase 21 (50.0%)

Trials by Status

completed2100%

Recent Activity

0 active trials
Showing 2 of 2
completedphase_2

A Study to Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to Balcinrenone and Placebo on Body Fluid and Electrolyte Handling and Energy Metabolism in Participants Over 50 Years of Age With Chronic Kidney Disease.

NCT05884866
completedphase_1

Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone

NCT06388616

Clinical Trials (2)

Showing 2 of 2 trials
NCT05884866Phase 2

A Study to Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to Balcinrenone and Placebo on Body Fluid and Electrolyte Handling and Energy Metabolism in Participants Over 50 Years of Age With Chronic Kidney Disease.

Completed
NCT06388616Phase 1

Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone

Completed

All 2 trials loaded

Drug Details

Intervention Type
Drug
Molecule Type
Small molecule
Total Trials
2

External References

ChEMBL
CHEMBL3916929

Names & Codes

Research Codes

Azd 9977